Home > > > > > Report Detail

Renal Diseases Drug Development Pipeline Review, 2018

Publisher Name :
Date: 19-Dec-2018
No. of pages: 154

Summary

This report provides an overview of the pipeline landscape for renal diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for chronic kidney disease (chronic renal failure), kidney fibrosis, polycystic kidney disease and end-stage kidney disease (end-stage renal disease), and features dormant and discontinued products.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of the feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol. There are 58 products in development for this indication.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant. There are 49 products in development for this indication.

Polycystic kidney disease is a disorder in which clusters of cysts develop primarily within the kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in the urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. There are 26 products in development for this indication.

End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant. There are five products in development for this indication.

Molecular targets in development for renal diseases include growth factor receptors, chemokines and kinases. Companies operating in this pipeline space include Angion Biomedica, Prolong Pharmaceuticals and Novartis.

Scope


  • Which companies are the most active within each pipeline?

  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

  • What are the most important R&D milestones and data publications to have happened in this disease area?


Reasons to buy


  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Renal Diseases Drug Development Pipeline Review, 2018

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7

2 Introduction 9
2.1 Renal Diseases Report Coverage 9
2.2 Chronic Kidney Disease (Chronic Renal Failure) - Overview 9
2.3 Kidney Fibrosis - Overview 9
2.4 Polycystic Kidney Disease - Overview 9
2.5 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview 9

3 Therapeutics Development 10
3.1 Chronic Kidney Disease (Chronic Renal Failure) 10
3.2 Kidney Fibrosis 19
3.3 Polycystic Kidney Disease 25
3.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 30

4 Therapeutics Assessment 33
4.1 Chronic Kidney Disease (Chronic Renal Failure) 33
4.2 Kidney Fibrosis 40
4.3 Polycystic Kidney Disease 48
4.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 56

5 Companies Involved in Therapeutics Development 61
5.1 Chronic Kidney Disease (Chronic Renal Failure) 61
5.2 Kidney Fibrosis 80
5.3 Polycystic Kidney Disease 93
5.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 99

6 Dormant Projects 102
6.1 Chronic Kidney Disease (Chronic Renal Failure) 102
6.2 Kidney Fibrosis 106
6.3 Polycystic Kidney Disease 107
6.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 109

7 Discontinued Products 110
7.1 Chronic Kidney Disease (Chronic Renal Failure) 110
7.2 Kidney Fibrosis 111
7.3 Polycystic Kidney Disease 111
7.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 111

8 Product Development Milestones 112
8.1 Chronic Kidney Disease (Chronic Renal Failure) 112
8.2 Kidney Fibrosis 127
8.3 Polycystic Kidney Disease 139

9 Appendix 153
9.1 Methodology 153
9.2 Coverage 153
9.3 Secondary Research 153
9.4 Primary Research 153
9.5 Expert Panel Validation 153
9.6 Contact Us 153
9.7 Disclaimer 154

List of Tables

Table 1: Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) 10
Table 2: Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure) 12
Table 3: Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure) 14
Table 4: Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure) 15
Table 5: Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure) 18
Table 6: Number of Products under Development for Kidney Fibrosis 19
Table 7: Number of Products under Development by Companies, Kidney Fibrosis 21
Table 8: Number of Products under Development by Universities/Institutes, Kidney Fibrosis 22
Table 9: Products under Development by Companies, Kidney Fibrosis 23
Table 10: Products under Development by Universities/Institutes, Kidney Fibrosis 25
Table 11: Number of Products under Development for Polycystic Kidney Disease, Kidney Fibrosis 26
Table 12: Number of Products under Development by Companies, Kidney Fibrosis 27
Table 13: Number of Products under Development by Universities/Institutes, Kidney Fibrosis 27
Table 14: Products under Development by Companies, Kidney Fibrosis 28
Table 15: Products under Development by Universities/Institutes, Kidney Fibrosis 29
Table 16: Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 30
Table 17: Number of Products under Development by Companies, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 31
Table 18: Products under Development by Companies, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 32
Table 19: Number of Products by Stage and Target, Chronic Kidney Disease (Chronic Renal Failure) 34
Table 20: Number of Products by Stage and Mechanism of Action, Chronic Kidney Disease (Chronic Renal Failure) 36
Table 21: Number of Products by Stage and Route of Administration, Chronic Kidney Disease (Chronic Renal Failure) 38
Table 22: Number of Products by Stage and Molecule Type, Chronic Kidney Disease (Chronic Renal Failure) 40
Table 23: Number of Products by Stage and Target, Kidney Fibrosis 42
Table 24: Number of Products by Stage and Mechanism of Action, Kidney Fibrosis 45
Table 25: Number of Products by Stage and Route of Administration, Kidney Fibrosis 46
Table 26: Number of Products by Stage and Molecule Type, Kidney Fibrosis 48
Table 27: Number of Products by Stage and Target, Polycystic Kidney Disease 50
Table 28: Number of Products by Stage and Mechanism of Action, Polycystic Kidney Disease 52
Table 29: Number of Products by Stage and Route of Administration, Polycystic Kidney Disease 54
Table 30: Number of Products by Stage and Molecule Type, Polycystic Kidney Disease 55
Table 31: Number of Products by Stage and Target, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 57
Table 32: Number of Products by Stage and Mechanism of Action, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 58
Table 33: Number of Products by Stage and Route of Administration, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 58
Table 34: Number of Products by Stage and Molecule Type, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 60
Table 35: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Allena Pharmaceuticals Inc 61
Table 36: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp 61
Table 37: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH 62
Table 38: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Arch Biopartners Inc 62
Table 39: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc 63
Table 40: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc 64
Table 41: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG 64
Table 42: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim GmbH 65
Table 43: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd 65
Table 44: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Ltd 66
Table 45: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Corvidia Therapeutics Inc 66
Table 46: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DiaMedica Therapeutics Inc 67
Table 47: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Dimerix Bioscience Pty Ltd 67
Table 48: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DURECT Corp 68
Table 49: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG 69
Table 50: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd 69
Table 51: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by KBP BioSciences Co Ltd 70
Table 52: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Klotho Therapeutics Inc 70
Table 53: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nash Pharmaceuticals Inc 71
Table 54: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG 71
Table 55: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health Inc 72
Table 56: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Opsidio LLC 72

List of Figures

Figure 1: Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) 10
Figure 2: Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure) 11
Figure 3: Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure) 14
Figure 4: Number of Products under Development for Kidney Fibrosis 19
Figure 5: Number of Products under Development by Companies, Kidney Fibrosis 20
Figure 6: Number of Products under Development for Polycystic Kidney Disease, Kidney Fibrosis 25
Figure 7: Number of Products under Development by Companies, Kidney Fibrosis 26
Figure 8: Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 30
Figure 9: Number of Products under Development by Companies, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 31
Figure 10: Number of Products by Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure) 33
Figure 11: Number of Products by Stage and Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure) 33
Figure 12: Number of Products by Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure) 35
Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure) 35
Figure 14: Number of Products by Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure) 37
Figure 15: Number of Products by Stage and Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure) 38
Figure 16: Number of Products by Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure) 39
Figure 17: Number of Products by Stage and Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure) 39
Figure 18: Number of Products by Top 10 Targets, Kidney Fibrosis 40
Figure 19: Number of Products by Stage and Top 10 Targets, Kidney Fibrosis 41
Figure 20: Number of Products by Top 10 Mechanism of Actions, Kidney Fibrosis 43
Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Fibrosis 44
Figure 22: Number of Products by Stage and Routes of Administration, Kidney Fibrosis 46
Figure 23: Number of Products by Top 10 Molecule Types, Kidney Fibrosis 47
Figure 24: Number of Products by Stage and Top 10 Molecule Types, Kidney Fibrosis 47
Figure 25: Number of Products by Top 10 Targets, Polycystic Kidney Disease 48
Figure 26: Number of Products by Stage and Top 10 Targets, Polycystic Kidney Disease 49
Figure 27: Number of Products by Top 10 Mechanism of Actions, Polycystic Kidney Disease 51
Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions, Polycystic Kidney Disease 51
Figure 29: Number of Products by Routes of Administration, Polycystic Kidney Disease 53
Figure 30: Number of Products by Stage and Routes of Administration, Polycystic Kidney Disease 53
Figure 31: Number of Products by Molecule Types, Polycystic Kidney Disease 54
Figure 32: Number of Products by Stage and Molecule Types, Polycystic Kidney Disease 55
Figure 33: Number of Products by Targets, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 56
Figure 34: Number of Products by Stage and Targets, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 56
Figure 35: Number of Products by Mechanism of Actions, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 57
Figure 36: Number of Products by Stage and Mechanism of Actions, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 58
Figure 37: Number of Products by Molecule Types, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 59
Figure 38: Number of Products by Stage and Molecule Types, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 59

  • Global Overactive Bladder Treatment Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93
    According to our LPI (LP Information) latest study, the global Overactive Bladder Treatment market size was valued at US$ 4989.1 million in 2023. With growing demand in downstream market, the Overactive Bladder Treatment is forecast to a readjusted size of US$ 6182.8 million by 2030 with a CAGR of 3.1% during review period. The research report highlights the growth potential of the global Overactive Bladder Treatment market. Overactive Bladder Treatment are expected to show stable growth......
  • Global Genitourinary Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 02-Jan-2024        Price: US 3380 Onwards        Pages: 110
    Market Overview of Global Genitourinary Drugs market: According to our latest research, the global Genitourinary Drugs market looks promising in the next 5 years. As of 2022, the global Genitourinary Drugs market was estimated at USD 30442.38 million, and it's anticipated to reach USD 32574.96 million in 2028, with a CAGR of 1.13% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global ......
  • Global Urinary Tract Infection Treatment Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Dec-2023        Price: US 3380 Onwards        Pages: 100
    Market Overview of Global Urinary Tract Infection Treatment market: According to our latest research, the global Urinary Tract Infection Treatment market looks promising in the next 5 years. As of 2022, the global Urinary Tract Infection Treatment market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. A urinary tract infection is an infection that can occur in any area of the urinary tract, i......
  • Global Overactive Bladder Treatment Market Research Report 2023, Forecast to 2028
    Published: 02-Nov-2023        Price: US 2680 Onwards        Pages: 130
    Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period. D......
  • Global Overactive Bladder Treatment Professional Survey Report 2023, Forecast to 2028
    Published: 02-Nov-2023        Price: US 3280 Onwards        Pages: 103
    Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period. D......
  • Global Overactive Bladder Treatment Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 17-Oct-2023        Price: US 3380 Onwards        Pages: 105
    Market Overview of Global Overactive Bladder Treatment market: According to our latest research, the global Overactive Bladder Treatment market looks promising in the next 5 years. As of 2022, the global Overactive Bladder Treatment market was estimated at USD 3983.87 million, and it's anticipated to reach USD 5304.63 million in 2028, with a CAGR of 4.89% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensiv......
  • Genitourinary Collaboration and Licensing Deals 2016-2023
    Published: 01-Oct-2023        Price: US 3995 Onwards        Pages: 150
    Genitourinary Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genitourinary deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of genitourinary deals from 2016 to 2023. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Underst......
  • Global Genitourinary Drugs Market Insights, Forecast to 2029
    Published: 14-Aug-2023        Price: US 4900 Onwards        Pages: 70
    The global Genitourinary Drugs market is projected to grow from US$ 29570 million in 2023 to US$ 35930 million by 2029, at a Compound Annual Growth Rate (CAGR) of 3.3% during the forecast period. The US & Canada market for Genitourinary Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029. The China market for Genitourinary Drugs is estimated to increase from $ million in 202......
  • Global Overactive Bladder Therapeutics Market Insights, Forecast to 2029
    Published: 28-Jun-2023        Price: US 4900 Onwards        Pages: 88
    Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device. Market Analysis and Insights: Global Overactive Bladder Therapeutics Market The global Overactive Bladder Therapeutics market is projected to grow from US$ 5240.8 million in 2023 t......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs